Arginine deprivation/citrulline augmentation with ADI-PEG20 as novel therapy for complications in type 2 diabetes
ADI-PEG20 treatment limited signs of DR and DPN and enhanced wound healing in db/db mice. Studies using BMDM suggest that the anti-inflammatory effects of ADI-PEG20 involve blockade of the JAK2-STAT1 signaling pathway via l-arginine depletion and l-citrulline production.
Authors
- John S. Bomalaski (ORCID: https://orcid.org/0000-0002-9454-7271)
- Ruth B. Caldwell (ORCID: https://orcid.org/0000-0003-0168-0354)
- Porsche Sandow
- Tahira Lemtalsi
- Modesto Rojas (ORCID: https://orcid.org/0000-0002-9441-3302)
- Robert W. Caldwell (ORCID: https://orcid.org/0000-0001-5009-0807)
- Ammar A. Abdelrahman (ORCID: https://orcid.org/0000-0002-6120-1231)
- Jing Wang (ORCID: https://orcid.org/0000-0002-9084-9985)
- Zhimin Xu (ORCID: https://orcid.org/0000-0002-4633-8969)
Institutions
- Augusta University (US)
- Polaris (United States) (US)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1016/j.molmet.2024.102020
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- James and Jean Culver Vision Discovery Institute, Georgia Regents University
- Augusta University
- National Institutes of Health
- National Eye Institute